



## OCREVUS

Administer Ocrelizumab under the close supervision of an experienced healthcare professional with access to appropriate medical support to manage severe reactions such as serious infusion reactions.

- **Initial dose:** 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion.
- **Subsequent doses:** single 600 mg intravenous infusion every 6 months.
- Observe the patient for at least one hour after the completion of the infusion.



**Table 1: Recommended dose, infusion rate, and infusion duration for Ocrevus**

| Ocrevus Dosing                     |                                 | Amount and Volume | Infusion Rate and Duration  |
|------------------------------------|---------------------------------|-------------------|---|
| Initial Dose<br>(two infusions)    | Infusion 1                      | 300 mg in 250 mL  | <ul style="list-style-type: none"> <li>• Start at 30 mL per hour</li> <li>• Increase by 30 mL per hour every 30 minutes</li> <li>• Maximum: 180 mL per hour</li> <li>• Duration: 2.5 hours or longer</li> </ul> |
|                                    | Infusion 2<br>(2 weeks later)   | 300 mg in 250 mL  |   |
| Subsequent Doses<br>(one infusion) | one infusion<br>(every 6 month) | 600 mg in 500 mL  | <ul style="list-style-type: none"> <li>• Start at 40 mL per hour</li> <li>• Increase by 40 mL per hour every 30 minutes</li> <li>• Maximum: 200 mL per hour</li> <li>• Duration: 3.5 hours or longer</li> </ul> |

## Tysabri

TYSABRI is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. YYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML).

- **The recommended dose of YYSABRI for multiple sclerosis:** 300 mg intravenous infusion over one hour every four weeks.



**Table 2: Recommended dose, infusion rate, and infusion duration for Tysabri**

| Tysabri Dosing | Infusion Rate and Duration                              |
|----------------|---|
| Initial Dose   | 300 mg intravenous infusion over one hour every 4 weeks |




### GAMUNEX-C

GAMUNEX-C is indicated for the treatment of CIDP in adults to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse.

**Initial Infusion Rate:** 2 mg/kg/min (0.02 mL/kg/min).

**Maintenance Infusion Rate** If the infusion is well tolerated, the rate may be gradually increased to a maximum of 8 mg/kg/min (0.08 mL/kg/min). For patients judged to be at risk for renal dysfunction or thrombosis, administer GAMUNEX-C at the minimum infusion rate practicable.



**Table 3: Recommended dose, infusion rate, and infusion duration for Gammunex-C**

| Indication | Initial Infusion Rate | Maintenance Infusion Rate |
|------------|-----------------------|---------------------------|
| PI         | 1 mg/kg/min           | 8 mg/kg/min               |
| ITP        | 1 mg/kg/min           | 8 mg/kg/min               |
| CIDP       | 2 mg/kg/min           | 8 mg/kg/min               |

### HOW DELIVERIT INFUSION & SPECIALTY PHARMACY CAN HELP

DeliverIt Pharmacy can help you understand a patient's coverage and OOP costs for IV home infusion therapy, prior authorizations, FREE medication deliveries, mobile IV-nurses, one-on-one patient training.



**CONTACT** your DeliverIt field reimbursement manager who can provide site-of-care education, including site options based on the patient's insurance coverage and requirements.



**E-SIGN REFERRAL FORMS** Learn more by visiting:  
[www.deliveritpharmacy.com/referral-forms](http://www.deliveritpharmacy.com/referral-forms)



SCAN TO LEARN MORE



**DELIVERIT™**  
Infusion & Specialty

**Download Guides by Visiting:** [www.deliveritpharmacy.com/neurology-IVIG](http://www.deliveritpharmacy.com/neurology-IVIG)